Protagonist Therapeutics expands board to 7, appoints Daniel Swisher as director

Protagonist Therapeutics, Inc

Board increased from 6 to 7 directors; Daniel N. Swisher, Jr. appointed as Class I director effective Oct 26, 2023.
Swisher most recently President of Jazz Pharmaceuticals (2018-2023); also serves on boards of Cerus and Corcept.
Receives $40,000 annual cash retainer and option for 45,000 shares at $14.21, vesting over 36 months.
Standard indemnification agreement entered; term runs until 2026 annual meeting.
No arrangements or family relationships with other directors or officers.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Daniel N. Swisher, Jr.

Class I Director

PTGX · Protagonist Therapeutics, Inc

Effective: 2023-10-26
Filed: October 30, 2023, 7:59 PM ET

appointed Daniel N. Swisher, Jr. to serve as a Class I director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Daniel N. Swisher, Jr. was appointed as Class I Director at Protagonist Therapeutics, Inc.

Action: appointed
Role: Class I Director

Exact text from the filing

appointed Daniel N. Swisher, Jr. to serve as a Class I director

View on SEC.gov

Protagonist Therapeutics, Inc filing history →

Source: SEC EDGAR

accession 0001104659-23-112592

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.